Search Result

Results for "

Ferroptosis-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Ferroptosis (17) Antibiotic (3) Apoptosis (8) Autophagy (8) Bacterial (3) FLT3 (5) Glutathione Peroxidase (3) Isotope-Labeled Compounds (1) NF-κB (3) Oxidative Phosphorylation (1) Raf (5) STAT (2) Transferrin Receptor (1) VEGFR (5)
By Research Areas:	Cancer (17) Infection (3) Inflammation/Immunology (3)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Ferroptosis AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145595

Ferroptosis inducer-1	Ferroptosis	Cancer
Ferroptosis inducer-1 (compound BX-3a) is a *Ferroptosis* inducer with antitumor potential ^[1].

HY-14655

Sulfasalazine 35+ Cited Publications NSC 667219	NF-κB Autophagy Apoptosis Ferroptosis Bacterial Antibiotic	Infection Inflammation/Immunology Cancer
Sulfasalazine (NSC 667219) is an anti-rheumatic agent for the research of rheumatoid arthritis and ulcerative colitis. Sulfasalazine can suppress NF-κB activity. Sulfasalazine is a type 1 *ferroptosis* inducer .

HY-10201A

Sorafenib Tosylate Maximum Cited Publications 188 Publications Verification Bay 43-9006 Tosylate	Raf VEGFR FLT3 Autophagy Ferroptosis Apoptosis	Cancer
Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for *Raf-1* and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a *ferroptosis* activator .

HY-10201

Sorafenib Maximum Cited Publications 188 Publications Verification Bay 43-9006	Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis	Cancer
Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for *Raf-1* and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a *ferroptosis* activator .

HY-153190A

W1131 TFA	Ferroptosis STAT	Cancer
W1131 TFA is a potent STAT3 inhibitor that induces ferroptosis. W1131 inhibits cancer progression in subcutaneous xenograft, organoid, and PDX models of gastric cancer. W1131 effectively alleviates cancer cell chemoresistance to 5-FU (HY-90006). W1131 regulates the cell cycle, DNA damage response, and oxidative phosphorylation, including the IL6-JAK-STAT3 pathway and the ferroptosis pathway .

HY-N11885

*Ferroptosis-IN-1*	Ferroptosis	Cancer
Ferroptosis-IN-1 is a A. campylantha diterpenes. Ferroptosis-IN-1 inhibits *ferroptosis* with an EC₅₀ value of 10 μM. Ferroptosis-IN-1 can be used for neuroinflammation diseases research ^[1].

HY-162717

GPX4-IN-11	Glutathione Peroxidase Ferroptosis	Cancer
GPX4-IN-11 (compound I14) is a potent inhibitor of GPX4, with the K_D of 45.7 μM. GPX4-IN-11 plays an important role in *ferroptosis* research .

HY-161928

GPX4 activator 1	Glutathione Peroxidase Ferroptosis	Cancer
GPX4 activator 1 (Compound A9) is a allosteric activator of GPX4 (K_d = 5.86 μM, EC₅₀ = 19.19 μM). GPX4 activator 1 can selectively act on ferroptosis and prevent the accumulation of intracellular lipid peroxides caused by ferroptosis inducers .

HY-14655R

Sulfasalazine (Standard)	NF-κB Autophagy Apoptosis Ferroptosis Bacterial Antibiotic	Infection Inflammation/Immunology Cancer
Sulfasalazine (Standard) is the analytical standard of Sulfasalazine. This product is intended for research and analytical applications. Sulfasalazine (NSC 667219) is an anti-rheumatic agent for the research of rheumatoid arthritis and ulcerative colitis. Sulfasalazine can suppress NF-κB activity. Sulfasalazine is a type 1 *ferroptosis* inducer .

HY-14655S1

Sulfasalazine-d3,15N NSC 667219-d₃,¹⁵N	Antibiotic Autophagy NF-κB Apoptosis Bacterial Ferroptosis Isotope-Labeled Compounds	Infection Inflammation/Immunology Cancer
Sulfasalazine-d₃, ¹⁵N is ¹⁵N and deuterated labeled Sulfasalazine (HY-14655). Sulfasalazine (NSC 667219) is an anti-rheumatic agent for the research of rheumatoid arthritis and ulcerative colitis. Sulfasalazine can suppress NF-κB activity. Sulfasalazine is a type 1 *ferroptosis* inducer .

HY-161948

Ferroptosis inducer-4	Ferroptosis	Cancer
Ferroptosis inducer-4 (Compound 5) is a ferroptosis (Ferroptosis) inducer with a structure featuring terminal double bonds introduced at the sn-2 position of phospholipids. Ferroptosis inducer-4 exhibits significant cytotoxicity towards HT-1080 cells, with an IC₅₀ of 18 μM. This cytotoxic mechanism involves the generation of lipid peroxides and oxidative damage to the cell membrane triggered by the terminal double bonds. Ferroptosis inducer-4 can be used for research on ferroptosis regulation .

HY-138153

JKE-1674 2 Publications Verification	Glutathione Peroxidase Ferroptosis	Cancer
JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into a nitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML-210 and is completely rescued by *ferroptosis* inhibitors .

HY-153190

W1131	Oxidative Phosphorylation STAT Ferroptosis	Cancer
W1131 is a potent STAT3 inhibitor, triggering *ferroptosis. W1131 suppresses cancer progression in gastric cancer cell subcutaneous xenograft model, organoids model, and PDX model. W1131 effectively alleviates chemical resistance of cancer cells to 5-FU (HY-90006). W1131 regulates cell cycle, DNA damage response, and oxidative phosphorylation, including IL6-JAK-STAT3* pathway and *ferroptosis* pathway .

HY-10201AR

Sorafenib Tosylate (Standard)	Raf VEGFR FLT3 Autophagy Ferroptosis Apoptosis	Cancer
Sorafenib (Tosylate) (Standard) is the analytical standard of Sorafenib (Tosylate). This product is intended for research and analytical applications. Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for *Raf-1* and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a *ferroptosis* activator .

HY-10201R

Sorafenib (Standard)	Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis	Cancer
Sorafenib (Standard) is the analytical standard of Sorafenib. This product is intended for research and analytical applications. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for *Raf-1* and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a *ferroptosis* activator .

HY-10201S2

Sorafenib-13C,d3 1 Publications Verification	Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis	Cancer
Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

HY-159569

TfR-1-IN-1	Transferrin Receptor Ferroptosis	Cancer
TfR-1-IN-1 (compound C4) is an inhibitor of transferrin receptor 1 (TfR-1) with anticancer activity. TfR-1-IN-1 strongly increases intracellular iron (II) levels as a driving force for the induction of *ferroptosis*. TfR-1-IN-1 significantly reduces the metabolic activity of ovarian cancer (A2780cis), breast cancer (MDA-MB 231), and leukemia (HL-60) cell lines with IC₅₀ values of 0.51, 0.46, and 0.48 μM, respectively ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N11885

*Ferroptosis-IN-1*	Structural Classification Ophryosporus axilliflorus Hieron. Terpenoids Labiatae Source classification Diterpenoids Plants	Ferroptosis
Ferroptosis-IN-1 is a A. campylantha diterpenes. Ferroptosis-IN-1 inhibits *ferroptosis* with an EC₅₀ value of 10 μM. Ferroptosis-IN-1 can be used for neuroinflammation diseases research ^[1].

Cat. No.	Product Name	Chemical Structure

HY-10201S2

Sorafenib-13C,d3 1 Publications Verification
Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

Sorafenib-13C,d3

1 Publications Verification

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

HY-14655S1

Sulfasalazine-d3,15N
Sulfasalazine-d₃, ¹⁵N is ¹⁵N and deuterated labeled Sulfasalazine (HY-14655). Sulfasalazine (NSC 667219) is an anti-rheumatic agent for the research of rheumatoid arthritis and ulcerative colitis. Sulfasalazine can suppress NF-κB activity. Sulfasalazine is a type 1 *ferroptosis* inducer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks